Contact
 
News about the Enterprise

IAS 2015 satellite: Mucosal Immunology Research in Canada - July 1, 2015

The Canadian HIV Vaccine Initiative (CHVI) Research and Development Alliance Coordinating Office (ACO) invite you to join a special satellite session at IAS 2015 on “Mucosal Immunology Research in Canada: Collaborative Contributions to the Field”. Mucosal immunology of the reproductive tract is a critical area of investigation for HIV vaccines, and this satellite aims to highlight the contribution of three of Canada’s leading teams working in this area.

Design, Test, Repeat: Paths to Elicit Neutralizing Antibodies A Virtual Mini-Symposium - May 13, 2015

A 2-hr virtual mini-symposium highlighting some of the latest research in the development of antibody-based HIV vaccines to be held on 22 May at 11am EST. This mini-symposium will focus on selected efforts to design immunogens, develop novel immunization regimens, and track the resulting antibody response with the goal of eliciting broadly protective neutralizing antibodies against HIV.

Enterprise Published a Consensus Summary Document on Vaccine-induced Sero-reactivity - May 11, 2015

HIV vaccine-induced sero-reactivity: A challenge for trial participants, researchers, and physicians - Antibody-inducing vaccines are a major focus in the preventive HIV vaccine field.  Because the most common tests for HIV infection rely on detecting antibodies to HIV, they may also detect antibodies induced by a candidate HIV vaccine.

Webinar Announcement: Understanding Interactions between Female Sex Hormones, Hormonal Contraception and HIV Susceptibility in Women - February 4, 2015

The Development Alliance Coordinating Office (ACO) invites you to join their webinar on Understanding interactions between female sex hormones, hormonal contraception and HIV susceptibility in women" with Dr. Charu Kaushic. This webinar will provide participants with a better understanding of the research and controversy surrounding hormonal contraception and links to increased HIV susceptibility and transmission in women.

Webinar Announcement: The anti-HIV Activity of Natural Killer Cells - September 22, 2014

The Canadian HIV Vaccine Initiative (CHVI) Research and Development Alliance Coordinating Office (ACO) invite you to join their webinar on “The anti-HIV activity of Natural Killer cells: Their role in protection from and control of HIV infectionwith Dr.

The Immune Space: A Concept and Template for Rationalizing Vaccine Development - August 21, 2014

The Enterprise and partners published a paper on "The Immune Space: A Concept and Template for Rationalizing Vaccine Development".  The “immune space template” proposed provides a standardized approach by which the quality, level, and durability of immune responses elicited in early human trials by a candidate vaccine can be described.

Keystone Symposium on HIV Vaccines: Adaptive Immunity and Beyond - April 22, 2014

The Keystone Symposium on HIV Vaccines: Adaptive Immunity and Beyond was held in Banff, Canada on 9-14 March, 2014.  The meeting’s main focus was the coordinated action of the humoral, cellular, and innate arms of the immune system in response to HIV vaccines or infection.  We bring you several stories that made a splash at the meeting and were discussed both in the conference center hallways and on the skiing lifts.

The game of tag and read

HIV Monoclonal Antibodies: A New Opportunity to Further Reduce Mother-to-Child HIV Transmission - April 14, 2014

In January 2013, the Enterprise held a consultation in Uganda on conducting efficacy trials of HIV prevention approaches in infants born to HIV-positive mothers in resource-limited settings (see the full report at http://www.vaccineenterprise.org/content/prevention-trials-infants).

CIHR-Bill & Melinda Gates Foundation launch team grant funding opportunity on Mucosal Immunology for HIV Vaccine Development - April 9, 2014

In the field of HIV vaccines, the prevention of HIV through mucosal infection has emerged as a critical area for investigation.  Mucosal surfaces, such as vaginal and rectal surfaces, are primary sites of HIV infection and offer potentially critical opportunities for protection.  A better understanding of early events in HIV exposure may be leveraged to develop new strategies to block infection or establish early, stringent control of HIV and prevent further spread.

Syndicate content
Global HIV Vaccine Enterprise, 64 Beaver Street, # 352, New York, NY 10004 | +1 212-461-3692 or toll free at +1-866-966-4483
All Content ©2005 - 2013 Global HIV Vaccine Enterprise   |   Terms of Use   |   Privacy Policy   |   Log In / My Account